Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

Next Previous
Trial Profile

Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Romidepsin (Primary) ; Cisplatin
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 23 Jan 2018 Status changed from active, no longer recruiting to recruiting.
    • 29 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jul 2015 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018 as per ClinicalTrials.gov record .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top